KPTI - Karyopharm Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.81
-0.64 (-6.12%)
At close: 4:00PM EST

9.81 0.00 (0.00%)
After hours: 4:57PM EST

Stock chart is not supported by your current browser
Previous Close10.45
Open10.48
Bid9.25 x 4000
Ask11.69 x 800
Day's Range9.80 - 10.59
52 Week Range9.00 - 21.71
Volume421,299
Avg. Volume801,642
Market Cap595.545M
Beta (3Y Monthly)4.95
PE Ratio (TTM)N/A
EPS (TTM)-2.96
Earnings DateMar 13, 2019 - Mar 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.09
Trade prices are not sourced from all markets
  • GlobeNewswire10 days ago

    Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 180,500 shares of Karyopharm’s common stock to eleven newly-hired employees, with a grant date of November 30, 2018.  The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $10.40 per share, the closing price of Karyopharm’s common stock on November 30, 2018. Each stock option vests over four years, with 25% of the original number of shares underlying the stock option vesting on the one-year anniversary of the applicable employee’s employment commencement date and an additional 1/48th of the shares vesting monthly thereafter, subject to the employee’s continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

  • GlobeNewswire10 days ago

    Karyopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in Relapsed/Refractory Multiple Myeloma at the American Society of Hematology 2018 Annual Meeting

    -- Oral Selinexor Achieves 26.2% Overall Response Rate in STORM Study, 4.4 Month Median Duration of Response, 8.6 Month Median Overall Survival and 15.6 Month Median Survival in.

  • ACCESSWIRE10 days ago

    The 4 Healthcare Stocks To Watch On Monday

    CORAL GABLES, FL / ACCESSWIRE / December 3, 2018 / Attention on Healthcare Market has continued to accelerate this quarter. The global healthcare IT market is expected to post a CAGR of over 8% during the period 2018-2022, according to the latest market research report by Technavio.

  • GlobeNewswire12 days ago

    Karyopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today reported positive top-line results from the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating selinexor, the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue. The data were highlighted in a poster presentation at the American Society of Hematology (ASH) 2018 Annual Meeting in San Diego.

  • GlobeNewswirelast month

    Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of KPTI earnings conference call or presentation 8-Nov-18 1:30pm GMT

    Q3 2018 Karyopharm Therapeutics Inc Earnings Call

  • Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Lags Revenue Estimates
    Zackslast month

    Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Lags Revenue Estimates

    Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 10.23% and -80.25%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Karyopharm Therapeutics: 3Q Earnings Snapshot

    The Newton, Massachusetts-based company said it had a loss of 79 cents per share. The results beat Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research ...

  • GlobeNewswirelast month

    Karyopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress

    -- U.S. Food and Drug Administration Accepts Karyopharm’s New Drug Application for Selinexor and Grants Priority Review; Assigns PDUFA Action Date of April 6, 2019 -- -- Fast.

  • GlobeNewswirelast month

    Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to selinexor, the Company’s first-in-class, oral SINE compound for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) who have received at least two prior therapies and are not eligible for high dose chemotherapy with stem cell rescue or CAR-T therapy. Selinexor is currently being studied in the ongoing Phase 2b SADAL study in patients with relapsed or refractory DLBCL who are not eligible for stem cell transplantation for which top-line results will be presented at the upcoming American Society of Hematology (ASH) 2018 Annual Meeting.

  • GlobeNewswirelast month

    Karyopharm to Present at the Jefferies 2018 London Healthcare Conference

    NEWTON, Mass., Nov. 07, 2018 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief.

  • GlobeNewswirelast month

    Karyopharm Therapeutics to Ring Nasdaq Closing Bell on November 6th

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that company executives, including founder Sharon Shacham PhD, MBA, President and Chief Scientific Officer and cofounder Michael G. Kauffman MD, PhD, Chief Executive Officer, will ring the Nasdaq Stock Market Closing Bell in celebration of the Company’s fifth listing anniversary. “Since our Company’s founding in 2008 and initial public offering in 2013, Karyopharm has made significant progress towards advancing our innovative pipeline of SINE compounds for the treatment of cancer and other major diseases,” said Michael G. Kauffman, MD, Ph.D., Chief Executive Officer of Karyopharm. “Most recently, the U.S. Food and Drug Administration accepted for filing with Priority Review our first New Drug Application seeking accelerated approval for our lead candidate, selinexor, a first-in-class, oral SINE compound, as a potential new treatment for patients with penta-refractory multiple myeloma.

  • GlobeNewswirelast month

    Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 127,500 shares of Karyopharm’s common stock to fifteen newly-hired employees, with a grant date of October 31, 2018.  The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $10.54 per share, the closing price of Karyopharm’s common stock on October 31, 2018. Each stock option vests over four years, with 25% of the original number of shares underlying the stock option vesting on the one-year anniversary of the applicable employee’s employment commencement date and an additional 1/48th of the shares vesting monthly thereafter, subject to the employee’s continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

  • GlobeNewswirelast month

    Karyopharm Announces Results of Clinical Studies Investigating Selinexor in Multiple Myeloma and Diffuse Large B-Cell Lymphoma to be Presented at the American Society of Hematology 2018 Annual Meeting

    -- Top-line Results from Phase 2b SADAL Study in DLBCL to be Presented --  --  Additional Results from the Pivotal Phase 2b STORM Study in Penta-Refractory Multiple Myeloma and.

  • Simply Wall St.last month

    Is Karyopharm Therapeutics Inc (NASDAQ:KPTI) Potentially Underrated?

    I’ve been keeping an eye on Karyopharm Therapeutics Inc (NASDAQ:KPTI) because I’m attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believe Read More...

  • GlobeNewswire2 months ago

    Karyopharm Therapeutics Announces Closing of Additional $22.5 Million of 3.00% Convertible Senior Notes Due 2025 Pursuant to Exercise in Full of Initial Purchasers’ Option

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that it has issued an additional $22.5 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the “notes”) pursuant to the exercise in full of the option to purchase additional notes granted to the initial purchasers in Karyopharm’s previously announced private offering of $150 million aggregate principal amount of notes to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The additional notes were sold on the same terms in all respects as the notes previously issued on October 16, 2018, and the terms of the additional notes are identical to those previously issued.

  • GlobeNewswire2 months ago

    Karyopharm Therapeutics Announces Management Change

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that Mike Falvey, Executive Vice President, Chief Financial Officer and Treasurer, intends  to leave the company to pursue other interests.   Mr. Falvey will continue  his current responsibilities until a successor is named to ensure there is no disruption in the financial leadership of  the Company. “Mike has played an important role at Karyopharm over the past year including in our two successful financings which will support the development of our clinical pipeline and first commercial launch anticipated in the first half of 2019,” said Michael G. Kauffman, MD, Ph.D., Chief Executive Officer of Karyopharm. Karyopharm Therapeutics Inc. (KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases.

  • GlobeNewswire2 months ago

    Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced the pricing of $150 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the “Notes”).  The Notes will be sold in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Karyopharm also granted to the initial purchasers of the Notes a 13-day option to purchase up to an additional $22.5 million aggregate principal amount of the Notes.

  • GlobeNewswire2 months ago

    Karyopharm Therapeutics Announces Proposed Private Offering of $150 Million of Convertible Senior Notes

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of convertible senior notes due 2025 (the “Notes”) in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Subject to certain conditions, on or after October 15, 2022, Karyopharm may redeem for cash all or a portion of the Notes. The Notes will be convertible at the option of holders of the Notes, upon satisfaction of certain conditions and during certain periods, into cash, shares of Karyopharm’s common stock, or a combination of cash and shares of Karyopharm’s common stock, at Karyopharm’s option. The interest rate, conversion rate, conversion price and certain other terms of the Notes will be determined at the time of pricing of the offering.

  • GlobeNewswire2 months ago

    U.S. Food and Drug Administration Accepts Karyopharm’s New Drug Application for Selinexor and Grants Priority Review

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its New Drug Application (NDA) seeking accelerated approval for selinexor, its first in class, oral SINE compound, as a new treatment for patients with penta-refractory multiple myeloma.  The FDA also granted Karyopharm’s request for Priority Review and assigned an action date of April 6, 2019 under the Prescription Drug User-Fee Act (PDUFA).  In its acceptance letter, the FDA has stated that it is currently planning to hold an advisory committee meeting to discuss this application.

  • GlobeNewswire2 months ago

    Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 108,900 shares of Karyopharm’s common stock to thirteen newly-hired employees, with a grant date of September 28, 2018.  The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $17.03 per share, the closing price of Karyopharm’s common stock on September 28, 2018.

  • GlobeNewswire3 months ago

    Karyopharm to Participate in Upcoming Investor Conferences

    NEWTON, Mass., Sept. 25, 2018 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the Company’s management.

  • GlobeNewswire3 months ago

    Selinexor Clinical Data to be Presented at the 21st Annual Meeting of the Chinese Society of Clinical Oncology

    --Two Oral Presentations Highlighting Previously Reported Phase 2 b STORM Data in Patients with Penta-Refractory Multiple Myeloma and Phase 2 b SADAL Data in Patients with Relapsed or Refractory Diffuse ...

  • Benzinga3 months ago

    The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut

    A roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 13.) Abbott Laboratories (NYSE: ABT ) Baxter International Inc ...